Brazil Sets National Accreditation Standard for Digital Health and Telemedicine

Brazil’s Ministry of Health and ONA have launched the country’s first accreditation manual for digital health, telemedicine, and telehealth services, establishing a formal quality and safety certification pathway for public and private providers.

Brazil's Ministry of Health and ONA have launched the country's first accreditation manual for digital health, telemedicine, and telehealth services, establishing a formal quality and safety certification pathway for public and private providers.

DIGITAL HEALTH · MAY 23, 2026 · LATIN AMERICA

A formal quality and safety framework for digital health services has arrived in Brazil. The Ministry of Health, in partnership with the Organização Nacional de Acreditação (ONA), has launched what both institutions describe as the country’s first accreditation manual specifically covering digital health, telemedicine, and telehealth services, according to the Ministry’s official announcement. The manual establishes a certification pathway applicable to both public and private sector providers, integrating Sistema Único de Saúde (SUS) guidelines with the operational realities of virtual care delivery at national scale.

System Implications

Until now, Brazil’s digital health sector has expanded without a unified national quality and safety accreditation standard. The new manual, per the Ministry’s announcement, addresses this gap by creating structured criteria that span interoperability requirements, care quality benchmarks, and safety protocols for digital and remote health services. The framework is designed to apply across the public-private spectrum — a design choice that, this suggests, reflects the Ministry’s recognition that telehealth in Brazil operates through both SUS channels and commercial platforms simultaneously.

The integration of SUS guidelines into the accreditation criteria is a structurally significant design decision. It positions the standard not merely as a voluntary quality marker but as a potential gateway for providers seeking to operate within or alongside the public system. Further data is needed to assess whether accreditation under this manual will become a mandatory prerequisite for SUS contracting or remain an optional certification tier.

Patient Access

Brazil’s population of 214 million — the figure cited in the Ministry’s framing of the initiative — accesses health services through a combination of SUS and private insurance channels. Telehealth has expanded materially as a delivery modality across both, particularly following regulatory changes that permitted remote consultations more broadly. The new accreditation standard could contribute to more consistent service quality for patients accessing virtual care, though no patient outcome data or access metrics tied to the manual’s launch have been published. The degree to which accreditation translates into measurable improvements in patient experience will depend on adoption rates and enforcement mechanisms not yet detailed in available documentation.

Industry and Payer Implications

For digital health platforms, telemedicine startups, and health systems operating virtual care programs in Brazil, the manual’s publication opens a compliance pathway that did not previously exist in standardized form. According to the Ministry’s announcement, the framework covers quality, safety, and interoperability — three dimensions that carry direct operational consequences for technology vendors, clinical workflow designers, and health plan administrators.

The immediate operational implication is that organizations will need to assess their current service architectures against the new accreditation criteria. This involves, at minimum, a gap analysis against the manual’s interoperability and safety standards, followed by decisions about whether to pursue formal ONA certification. For health plans and payers contracting with digital health providers, the existence of a national standard may be associated with shifts in vendor selection criteria and contract requirements — though no payer has announced any such policy change to date.

Startups and platform operators entering the Brazilian market, or those scaling existing operations, now face a defined compliance reference point. Whether that reference point becomes a market-entry threshold or remains a differentiating credential will likely depend on regulatory and procurement decisions that follow the manual’s adoption.

Regulatory and Legal Considerations

The manual has been launched with Ministry of Health support, per the official announcement. It does not, based on available information, carry the status of a binding regulatory instrument at this stage — ONA accreditation in Brazil operates as a voluntary certification system, and there is no indication that the digital health manual has been issued as a mandatory compliance requirement by ANVISA or any other regulatory authority. Organizations should treat the current status as a published voluntary standard pending any subsequent regulatory action that would alter its legal standing. No enforcement proceedings, investigations, or litigation are associated with this launch based on available information.

Counterpoint

The principal counterargument is that voluntary accreditation frameworks in Brazil’s health sector have historically struggled to achieve broad adoption without a direct reimbursement or contracting incentive attached. ONA accreditation for hospitals and clinics, while respected, covers a fraction of eligible facilities. A digital health manual that lacks a mandatory link to SUS contracting eligibility, ANVISA licensing, or health plan reimbursement criteria may generate limited uptake among the smaller telemedicine operators and startups that represent the fastest-growing segment of the market. The specific friction is financial: certification processes carry administrative and operational costs, and without a clear revenue or access benefit tied to accreditation status, the cost-benefit calculus for smaller platforms is unfavorable. The manual’s strategic value depends heavily on whether the Ministry and ANS subsequently embed it into procurement or coverage frameworks — a step that has not been confirmed.

Strategic Outlook

The launch of the manual establishes a reference architecture that regulators, payers, and procurement bodies can adopt or mandate in subsequent policy cycles. One possible scenario is that ANS incorporates accreditation criteria from the manual into its oversight of health plan digital service offerings, which would create a de facto compliance requirement for the private insurance market. Absent such a linkage, the standard’s market impact will be shaped primarily by reputational and competitive dynamics rather than regulatory compulsion.

For international digital health companies evaluating Brazil as an expansion market, the manual signals that the regulatory environment is maturing toward structured quality expectations — a development that may be associated with higher barriers to entry over time, but also with greater market predictability for compliant operators.

What to Watch

  1. Whether ANS or ANVISA issues guidance referencing the ONA digital health manual as a compliance or contracting criterion within the next regulatory cycle.
  2. ONA’s publication of a formal certification timeline and fee structure for digital health providers seeking accreditation under the new manual.
  3. Ministry of Health announcements linking SUS digital health contracting or telehealth reimbursement to accreditation status under this framework.
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

Closing Insight

The manual’s most consequential long-term effect may not be on the platforms that pursue accreditation, but on those that do not: as institutional buyers — health plans, hospital networks, state health secretariats — begin referencing the standard in procurement language, non-accredited providers may find themselves structurally excluded from the contracts that define scale in Brazil’s digital health market.

HealthSignals Intelligence

Brazil’s Digital Health Accreditation: Regulatory Pathway

From voluntary certification to national standard — how Brazil is structuring quality oversight for telehealth at scale

2020 — ANS Voluntary Accreditation Framework

ANS establishes voluntary accreditation program for private health plan operators (RN 452), covering organizational management and care quality — certified by Inmetro-recognized bodies.

2022 — Good Practices Certification Expanded

ANS RN 506 launches the PCBP program, extending certification to specific care networks and care pathways within private operators — reinforcing quality benchmarks ahead of digital care growth.

March 2025 — Accreditation Rules Updated (RN 630)

ANS revises operator accreditation requirements, tightening recognition criteria for accrediting entities — signaling regulatory maturation as digital and telehealth services scale across both SUS and private sectors.

2026 — ONA National Standard (aligned with Ministry of Health guidelines)

Brazil’s first national accreditation standard for digital health and telemedicine integrates SUS guidelines with private sector quality frameworks — creating a unified certification pathway for safety, quality, and interoperability as telehealth expands nationwide.

Strategic Implication: For pharma, payers, and investors, Brazil’s accreditation architecture signals a maturing regulatory environment where digital health market entry will increasingly require certified quality compliance — creating both barriers and credibility premiums for compliant operators.

Sources: ANS RN 506 (2022), ANS RN 630 (March 2025), ANS Accreditation Program portal. Analysis: HealthSignals.

THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related